Journal of Liposome Research最新文献

{"title":"Preparation of ROS-responsive baicalin liposomes and evaluation of their therapeutic effects on hemorrhagic stroke-induced brain injury.","authors":"Bing Luo, Jiankang Huang, Jing Wang, Ling Liu, Jingjing Liu, Yize Lv, Jie Wang","doi":"10.1080/08982104.2026.2641478","DOIUrl":"10.1080/08982104.2026.2641478","url":null,"abstract":"<p><p>As the principal active ingredient of <i>Scutellaria baicalensis</i> Georgi, Baicalin demonstrates anti-inflammatory and neuroprotective activities with the potential to repair brain injury. Nonetheless, poor solubility in water and low bioavailability of Ba limits its clinical application. To enhance solubility, bioavailability, and lesion-site delivery of Ba to reactive oxygen species (ROS)-rich lesions, we developed a ROS-responsive liposomal delivery system using DSPE-SS-PEG. Thin-film hydration was utilized to prepare the Ba-loaded liposomes (Ba@DSPE-SS-PEG-Liposome), before optimization <i>via</i> response surface methodology. The liposomes were comprehensively characterized <i>in vitro</i> using drug loading, particle size, morphology, release behavior, and encapsulation efficiency. Under high ROS conditions, internalization of ROS-responsive (DSPE-SS-PEG-modified) formulation was improved based on findings of cellular uptake studies. At the ischemic site, liposomes promoted targeted accumulation and prolonged systemic circulation of the drug. Neurological deficits, cerebral edema, and neuronal apoptosis were significantly alleviated in a rat model of hemorrhagic stroke by the ROS-responsive liposomes, which outperformed conventional liposomes and free Ba. Synergistic regulation of inflammatory and oxidative stress pathways mediated these therapeutic benefits. Altogether, the therapeutic efficacy of BA in hemorrhagic stroke can be effectively enhanced by this ROS-responsive (stimuli-responsive) liposomal system.</p>","PeriodicalId":16286,"journal":{"name":"Journal of Liposome Research","volume":" ","pages":"272-289"},"PeriodicalIF":4.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147433443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Control of breast cancer via anastrozole-loaded transbilosomes.","authors":"Marwa H Elkarmalawy, Marwa M Nagib, Amany Belal, Samar F Miski, Saeed Saad A Alghamdi, Alaa Ismail, Asmaa M El-Kalaawy, Alshimaa Mohamed Abdelmohymen, Amr Gamal Fouad","doi":"10.1080/08982104.2026.2664882","DOIUrl":"10.1080/08982104.2026.2664882","url":null,"abstract":"<p><p>Breast cancer (BC) represents a serious threat to public health worldwide, especially for women. Anastrozole (ATZ) is recognized as a therapeutic candidate for treating BC. However, its poor solubility and bioavailability result in low efficacy. This study set out to improve ATZ's ability to manage BC by developing a nasal spray formulation of ATZ-loaded transbilosome (ALT) that would increase ATZ's sustainability, bioavailability, targeting, and efficacy. Design Expert software was used to make different ALT formulations, and the optimum one was chosen. The optimal ALT formulation was then evaluated <i>in vivo</i> using an Ehrlich-induced BC mouse model to assess its efficacy, bioavailability, targeting, and safety. The optimized ALT formulation consists of phospholipid (271.62 mg), Span 60 (24.69 mg), and sodium deoxycholate (18.19 mg). Optimized ALT outperformed free ATZ by 77% in sustainability, 7.88 times in bioavailability, 11.62 times in permeation, and 5.52 times in targeting. Tumor volume, mortality rates, and levels of the biomarkers Ca-15-3 and Ca-27.29 were all significantly lower in the nasal ALT group compared to the disease group by 99.08%, 23.33%, 97.76%, and 98.73%, respectively. The nasal ALT formulation is considered safe because it did not adversely affect kidney or liver functions. In conclusion, the nasal ALT formulation shows potential as a therapy for managing BC.</p>","PeriodicalId":16286,"journal":{"name":"Journal of Liposome Research","volume":" ","pages":"360-373"},"PeriodicalIF":4.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147838897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refining <i>in vitro</i> cytotoxicity of α-mangostin against triple-negative breast cancer using dequalinium-modified liposomal nanocarrier.","authors":"Satrialdi, Devira Fitriana, Vern Natalie Setiawan, Salmahitasya Raniaputri, Wina Adisty Zafira, Ebrahim Sadaqa, Adik Ahmadi, Catur Riani, Diky Mudhakir","doi":"10.1080/08982104.2026.2635603","DOIUrl":"10.1080/08982104.2026.2635603","url":null,"abstract":"<p><p>Triple-negative breast cancer (TNBC) lacks estrogen, progesterone, and HER2 receptors, resulting in limited treatment options and poor outcomes. Mitochondria play vital roles in tumor progression and metastasis; thus, targeting their function with mitochondria-toxic agents, such as α-mangostin (α-M), could be an effective treatment for cancer, especially for TNBC. In this study, we attempted to develop a mitochondria-targeted nanoplatform, namely LipoDQ, containing α-M for suppressing the growth of TNBC. We first optimized the composition of the LipoDQ system to construct α-M LipoDQ following a comprehensive physical particle characterization. Subsequently, we assessed its cellular uptake and mitochondrial accumulation, utilizing flow cytometry and confocal laser scanning microscopy, respectively. Finally, we validated the cytotoxic and migratory inhibition activities of α-M LipoDQ in TNBC cells. As a result, the developed α-M LipoDQ exhibited a stable, spherical shape of 150.1 ± 4.0 nm with a uniform distribution and positive surface charge. The presence of DQ on the surface of the LipoDQ system significantly improved cellular uptake efficiency, as well as the mitochondrial accumulation of α-M. Furthermore, transfection with α-M LipoDQ significantly reduced the viability of TNBC cells compared to α-M solution or non-targeted α-M liposome. Additionally, α-M LipoDQ inhibited TNBC cell migration, indicating its potential as an alternative treatment strategy for TNBC. This finding suggests that targeting mitochondrial function in the treatment of TNBC can be beneficial and warrants further investigation in preclinical research.</p>","PeriodicalId":16286,"journal":{"name":"Journal of Liposome Research","volume":" ","pages":"261-271"},"PeriodicalIF":4.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147317422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liposomal iron bisglycinate hydrochloride, but not free iron bisglycinate, enhances serum iron restoration in a mouse model of inflammation-induced anemia: a preliminary study.","authors":"Meygal Kahana Sela, Amir Agbaria, Noor Omari Knani, Rami Awida, Abraham Weizman, Moshe Gavish","doi":"10.1080/08982104.2026.2647943","DOIUrl":"10.1080/08982104.2026.2647943","url":null,"abstract":"<p><p>Iron deficiency is a major global health concern, particularly in inflammation-related anemia (IRA), where iron absorption and mobilization are impaired. Liposomal encapsulation may help enhance the bioavailability and efficacy of iron supplements. This study aimed to evaluate the therapeutic efficacy of orally administered liposomal iron bisglycinate hydrochloride (LIBH), compared to free iron bisglycinate hydrochloride (FIBH), in restoring serum iron levels in a mouse model of lipopolysaccharide (LPS)-induced anemia of inflammation (LIAI). Male C57BL/6 mice received intraperitoneal LPS (5 mg/kg) to induce LIAI and were simultaneously treated with either FIBH or LIBH (1 mg/kg, oral). Liposomes (150-200 nm) exhibited high encapsulation efficiency (93%) and stability (-38 to -45 mV zeta potential). Serum iron levels were measured 24 hours post-treatment. LPS administration significantly reduced serum iron levels. LIBH restored serum iron levels by 35 - 65% compared to baseline (<i>p</i> < 0.005), outperforming FIBH (0 - 16%, <i>p</i> = NS). Electron microscopy confirmed the structural integrity of LIBH liposomes. It seems that LIBH supplementation significantly improves serum iron levels in LIAI and may represent a superior alternative to traditional free iron therapy, particularly in inflammatory conditions. Further studies are warranted to assess its efficacy in other models of anemia.</p>","PeriodicalId":16286,"journal":{"name":"Journal of Liposome Research","volume":" ","pages":"316-320"},"PeriodicalIF":4.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147698947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of cationic amphiphilic drugs on mRNA lipoplex-induced protein expression.","authors":"Yoshiyuki Hattori, Hayato Kawasaki, Maya Nishiyama, Mizuki Shinkawa, Kumi Kawano","doi":"10.1080/08982104.2026.2658704","DOIUrl":"10.1080/08982104.2026.2658704","url":null,"abstract":"<p><p>In this study, we investigated the impact of cationic amphiphilic drugs (CADs) on <i>in vitro</i> and <i>in vivo</i> protein expression following administration of mRNA lipoplexes. The mRNA lipoplexes were formulated using a modified ethanol injection method and applied to human hepatoma HuH-7 cells, human prostate cancer PC-3 cells, and DC2.4 mouse dendritic cells in the presence of various CADs: ebastine (EBS), loperamide (LPM), carvedilol (CVD), nortriptyline (NRT), desloratadine (DSL), and chloroquine (CQ). <i>In vitro,</i> high luciferase (Luc) expression was induced by Luc mRNA lipoplexes in the presence of EBS, LPM, or CVD, whereas similar effects were not observed with NRT, DSL, or CQ. This enhanced expression was attributed to inhibition of lysosomal acidification rather than changes in cellular uptake or mRNA translation efficiency. Intravenous administration of Luc mRNA lipoplexes into the tail vein of mice increased Luc activity in the lungs and spleen; co-administration with EBS or CVD further increased protein expression in the lungs without affecting expression in the spleen. Furthermore, induction of ovalbumin (OVA)-specific antibodies by OVA mRNA lipoplex administration was suppressed by EBS, attributed to reduced TNF-α production in the spleen, whereas CVD did not elicit similar effects. These findings suggest that EBS and CVD promote mRNA lipoplex-mediated protein expression in cultured cells and mouse lung tissue. However, EBS also diminishes antibody responses triggered by mRNA lipoplexes. Accordingly, caution is warranted when administering lipid-based mRNA vaccines to patients taking CADs, as these drugs may influence vaccine efficacy and safety.</p>","PeriodicalId":16286,"journal":{"name":"Journal of Liposome Research","volume":" ","pages":"347-359"},"PeriodicalIF":4.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147773916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of cationic:helper lipid ratios and PEG-lipid architecture on siRNA delivery performance of 2X3-based liposomal formulations.","authors":"Daniil V Gladkikh, Elena V Shmendel, Mikhail A Maslov, Marina A Zenkova, Elena L Chernolovskaya","doi":"10.1080/08982104.2026.2643327","DOIUrl":"10.1080/08982104.2026.2643327","url":null,"abstract":"<p><p>Small interfering RNA (siRNA) therapeutics hold great potential for treating genetic disorders and cancer, yet their clinical translation remains constrained by the challenge of efficient delivery. This study systematically investigates the effect of the ratio between cationic and helper lipids in the formulation of 2X3-DOPE-based liposomes, including formulations equipped with PEG-shielding lipoconjugates differing in structure and PEG (polyethylene glycol) length on the efficiency of siRNA accumulation and gene silencing. Changing the 2X3-to-DOPE cationic-to-helper lipid molar ratio from 1:1 to 1:2 differentially affects the properties of formulations across N/P ratios, but has little effect on the transfection efficiency in cell culture. Pharmacokinetic analysis in mice revealed that siRNA complexed with PEGylated P2000 1:1 liposomes achieved the highest plasma concentration (14.23 pmol/mL at 15 min), representing a 41-fold increase over non-PEGylated formulation, but exhibited only moderate hepatic <i>Ttr</i> gene silencing (35.5%). Remarkably, 2X3 1:1 liposomes demonstrated exceptional silencing efficacy (93.9% knockdown), while increasing helper lipid content reduced the activity of complexes with 2X3 1:2 liposomes (80.2% decrease in <i>Ttr</i> gene knockdown). The study shows that siRNA therapeutics require formulation-specific balance between systemic stability, hepatocyte uptake, endosomal escape, and RISC loading and highlighted the indispensable role of cationic-to-helper lipid ratio optimization to maximize bioactivity without sacrificing PEG-mediated protection.</p>","PeriodicalId":16286,"journal":{"name":"Journal of Liposome Research","volume":" ","pages":"290-302"},"PeriodicalIF":4.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147521184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of immunoliposomes with E-Selectin affinity to target endothelial inflammation: direct comparison of antibody types.","authors":"Foteini Gkartziou, Valérie Petegnief, Maria Kannavou, Ana Cristina Flavián-Lázaro, Nuria Pascual, Leonardo Marquez-Kisinousky, Pilar Marco, Anna M Planas, Sophia G Antimisiaris","doi":"10.1080/08982104.2026.2645864","DOIUrl":"10.1080/08982104.2026.2645864","url":null,"abstract":"<p><p>Inflamed endothelium targeting <i>via</i> E-Selectin is a promising strategy for drug delivery across the neurovascular interface, however, exploitation of the strategy by immunoliposomes remains limited. Furthermore, the high cost of antibodies poses a practical barrier for iterative formulation optimization. In this study, we developed two E-Selectin-targeted immunoliposome types incorporating either a commercially available monoclonal antibody (mAb) or a mAb produced in-house from a proprietary hybridoma line. Pre-formed liposomes were functionalized through maleimide-PEG conjugation and characterized for size distribution (by DLS), zeta potential (electrophoretic mobility), and Mab attachment (%). Immunoliposome targeting efficacy was assessed on brain microvascular endothelial cells under basal conditions and also after LPS-induced inflammation (to mimic pathological E-Selectin upregulation), by flow cytometry. Both immunoliposome formulations had similar characteristics and demonstrated significantly enhanced binding to endothelial cells relative to non-targeted liposomes, under both conditions studied. Furthermore, uptake by inflamed cells was always significantly higher than by non-inflamed cells. No differences in (<i>in vitro</i>) targeting magnitude between the commercial and hybridoma-derived Mab's were quantified, proving their comparable performance despite substantial differences in mAb cost. The current findings highlight the feasibility of substituting commercial mAbs with hybridoma-derived ones during preclinical development of targeted nanocarriers, as a strategy to reduce expenses while preserving their specificity and functional performance. Furthermore, it is demonstrated that E-Selectin targeted immunoliposomes are promising drug delivery systems for treatment of inflamed vasculature, justifying further <i>in vitro</i> and <i>in vivo</i> exploitation.</p>","PeriodicalId":16286,"journal":{"name":"Journal of Liposome Research","volume":" ","pages":"303-315"},"PeriodicalIF":4.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147474017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A mechanistic study of mitochondria-targeted PCSK9 liposomes attenuate oxidative damage in carotid artery plaques.","authors":"Liwei Zhang, Guanyu Chen, Yuhai Bai, Qi Li","doi":"10.1080/08982104.2026.2651190","DOIUrl":"10.1080/08982104.2026.2651190","url":null,"abstract":"<p><p>Atherosclerotic plaque instability is a direct cause of cardiovascular and cerebrovascular events. In this study, a mitochondria-targeted liposome (LIP), modified with triphenylphosphonium (TPP) to enable specific mitochondrial delivery, was innovatively constructed to encapsulate a PCSK9 inhibitor (TPP-LIP@PCSK9). The aim was to explore a novel strategy for stabilizing plaques by restoring mitochondrial function in endothelial cells. Characterization results showed that TPP-LIP@PCSK9 possesses favorable nano-characteristics, and its targeting capability was confirmed through mitochondrial co-localization experiments. In an Apoe^-/- mouse model, TPP-LIP@PCSK9 treatment significantly inhibited carotid artery plaque progression and reduced oxidative damage within the plaques. It markedly enhanced the activity of antioxidant enzymes (T-SOD, CAT) and decreased the level of lipid peroxidation products (MDA) in plaque tissue. Further analysis by Western blot and transcriptomics revealed that TPP-LIP@PCSK9 downregulated the mitochondrial damage marker proteins PINK1/Parkin, activated the Nrf2/UCP2-mediated antioxidant pathway, and modulated signaling pathways closely associated with oxidative stress and metabolism. This study is the first to report the direct role of PCSK9 in mitochondrial oxidative damage within plaque endothelial cells and to achieve effective intervention via nanotechnology, providing a new perspective for the treatment of atherosclerosis.</p>","PeriodicalId":16286,"journal":{"name":"Journal of Liposome Research","volume":" ","pages":"321-331"},"PeriodicalIF":4.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147574323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"On the use of high ethanol content dialysis media in <i>in vitro</i> release studies of lipid nanocarriers.","authors":"Sophia G Antimisiaris","doi":"10.1080/08982104.2026.2637049","DOIUrl":"10.1080/08982104.2026.2637049","url":null,"abstract":"","PeriodicalId":16286,"journal":{"name":"Journal of Liposome Research","volume":" ","pages":"260"},"PeriodicalIF":4.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147326377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microneedle assisted drug delivery of liposome loaded with selegiline hydrochloride for effective management of Parkinson's disease intervention.","authors":"Kartik Bhairu Khot, Jobin Jose, Gopika Gopan, Akshay Bandiwadekar, Shridhar Deshpande N, Naseer Maliyakkal, Ketura Kambampaty","doi":"10.1080/08982104.2026.2657323","DOIUrl":"10.1080/08982104.2026.2657323","url":null,"abstract":"<p><p>Microneedles assisted transdermal delivery of cationic liposomes loaded with selegiline hydrochloride is an innovative approach to treat the symptoms of Parkinson's disease. Previously optimized liposomes of selegiline hydrochloride (SH-LP3) were incorporated within the microneedle array by solvent casting method. The microneedle patch (SH-LP3-MNP) had uniform thickness with an optimum moisture percentage that maintains the mechanical strength of the needle tips. Through an FT-IR study, selegiline and PVA were found to be compatible, showing their prominent functional group. The shape, size, and needle tips of the microneedle were confirmed via SEM analysis. <i>Ex vivo</i> permeability study resembles higher permeation of liposomes through SH-LP3-MNP formulation when compared with SH-MNP. This study also resulted in lower drug retention within the skin membrane. Pharmacokinetic evaluation in Wistar rats indicated that the liposome-loaded microneedles released selegiline in a sustained manner and maintained drug levels in the bloodstream for a longer period, which was reflected by a higher AUC value. The sensory motor coordination of rats improved in microneedle assisted delivery as shown in <i>in vivo</i> antiparkinson disease study. Biochemical tests supported these findings by showing increased antioxidant enzyme activity, reduced lipid peroxidation, and a noticeable rise in dopamine levels in brain tissue. A histopathological study showed improved neuronal regeneration for the SH-LP3-MNP formulation. Through these findings, it was reported that the SH-LP3-MNP formulation is a promising approach for delivering liposomes loaded with selegiline through the skin for the treatment of Parkinson's disease symptoms.</p>","PeriodicalId":16286,"journal":{"name":"Journal of Liposome Research","volume":" ","pages":"332-346"},"PeriodicalIF":4.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147698923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}